FGFR1 and uterine carcinosarcoma: We have identified a number of molecular alterations that may be targetable using compounds currently under clinical use or under clinical trial study, and demonstrated preclinical evidence in support of targeting amplified/over-expressed FGFR1 in uterine carcinosarcoma.